Looking for new trends in penny stocks can be hard. But a few trends emerge quickly and before you know it, everyone’s talking about it. We saw this with marijuana stocks early on. Many thought it to be a “fad” or “just a short-term trend”. But now an entire, multi-billion-dollar industry has been created. One of the new trend emerging in the stock market today is psychedelic stocks. Psilocybin, MDMA, Ayahuasca & Other “Mind Medicine” Are Propelling Psychedelic Stocks right now.
This new class of stock goes by a number of names: “mushrooms stocks,” “ayahuasca stocks,” “MDMA stocks,” and plenty of other names. But the best part is that most, if not all are psychedelic penny stocks right now. Some of the big-name investors include former cannabis pioneer Bruce Linton and even infamous Shark Tank star Kevin O’Leary.
Why Psychedelic Stocks / Mushroom Stocks?
With any new industry, the first-movers are the big risk takers. You don’t necessarily know what the end of the road looks like. Yet along the way, speculation and a little bit of progress can drive things like marijuana stocks and mushroom stocks. If you’re looking at psychedelic penny stocks right now, you need to understand there’s a lot of risk involved.
But at the end of the day, if you understand this risk, mushroom stocks could become another early opportunity at a very young industry. Will it see a similar growth trajectory as marijuana stocks did or is this truly a fad? That is something yet to be seen considering the infancy of this industry right now
A Blooming Opportunity For Investors To Cash In On Mushroom Stocks
Once A Fringe Industry Now Being Called The Biggest Opportunity Since Legal Cannabis
July 5, 2020
8 minute read
Are Mushroom Penny Stocks Next To Boom After This $27M Bet?
Whether You Call Them Psychedelic Stocks, Shroom Stocks, Or Psilocybin Stocks, These Are Gaining Attention Right Now
June 29, 2020
6 minute read
Psychedelic Penny Stocks To Watch Amid The Mushroom Boom
Psilocybin, MDMA, Ayahuasca & Other “Mind Medicine” Are Propelling Psychedelic Stocks; Are…
May 20, 2020
6 minute read
Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19